en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
2/2009
vol. 47
 
Share:
Share:
more
 
 
abstract:
Review paper

Tocilizumab – interleukin 6 receptor inhibitor – a new therapeutic option in the treatment of rheumatoid arthritis

Magdalena Szmyrka-Kaczmarek
,
Piotr Wiland

Reumatologia 2009; 47, 2: 85–94
Online publish date: 2009/06/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Interleukin 6 is a pleiotropic cytokine which regulates the innate and adaptive immune response, inflammation and acute phase response. It plays a significant role in various chronic inflammatory processes including rheumatoid arthritis. The inhibition of IL-6 signal transduction by monoclonal antibodies against IL-6 receptor is a new efficient and safe therapeutic method in rheumatoid arthritis
keywords:

interleukin 6, interleukin 6 receptor, tocilizumab, rheumatoid arthritis







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.